Literature DB >> 27230442

Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada.

Robert B Hopkins1, Natasha Burke2, Charlene Fell3, Genevieve Dion4, Martin Kolb5.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a rare disease, with estimates of prevalence varying considerably across countries due to paucity in data collection. The aim of this study was to investigate the prevalence and incidence of IPF in Canada using administrative data requiring minimal extrapolation.We used mandatory national administrative data from 2007-2011 to identify IPF cases of all ages with an International Classification of Diseases (Version 10, Canadian) diagnosis code of J84.1. We used a broad definition that excluded cases with subsequent diagnosis of other interstitial lung diseases, and a narrow definition that required further diagnostic testing prior to IPF diagnosis. We explored survival and quality of life.For all ages, the broad prevalence of IPF was 41.8 per 100 000 (14 259 cases) and was higher for men. The incidence rate was 18.7 per 100 000 (6390 cases) and was higher for men. The narrow prevalence was 20.0 per 100 000 (6822 cases) and incidence was 9.0 per 100 000 (3057 cases). The 4-year risk of death was 41.0% and the quality of life with IPF after 2 years was lower than for Global Initiative for Chronic Obstructive Lung Disease stage IV chronic obstructive pulmonary disease.Using comprehensive national data, the prevalence of IPF in Canada was higher than other national estimates, suggesting that either IPF may be more common in Canada or that data capture may have been previously limited.
Copyright ©ERS 2016.

Entities:  

Mesh:

Year:  2016        PMID: 27230442     DOI: 10.1183/13993003.01504-2015

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  28 in total

1.  Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris.

Authors:  Boris Duchemann; Isabella Annesi-Maesano; Camille Jacobe de Naurois; Shreosi Sanyal; Pierre-Yves Brillet; Michel Brauner; Marianne Kambouchner; Sophie Huynh; Jean Marc Naccache; Raphael Borie; Jacques Piquet; Arsène Mekinian; Jerôme Virally; Yurdagul Uzunhan; Jacques Cadranel; Bruno Crestani; Olivier Fain; Francois Lhote; Robin Dhote; Nathalie Saidenberg-Kermanac'h; Paul-André Rosental; Dominique Valeyre; Hilario Nunes
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

2.  Activated human T lymphocytes inhibit TGFβ-induced fibroblast to myofibroblast differentiation via prostaglandins D2 and E2.

Authors:  Shannon H Lacy; Amali P Epa; Stephen J Pollock; Collynn F Woeller; Thomas H Thatcher; Richard P Phipps; Patricia J Sime
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-12-20       Impact factor: 5.464

3.  Epidemiology of idiopathic pulmonary fibrosis: a population-based study in primary care.

Authors:  Sergio Harari; Michele Davì; Alice Biffi; Antonella Caminati; Alessandra Ghirardini; Valeria Lovato; Claudio Cricelli; Francesco Lapi
Journal:  Intern Emerg Med       Date:  2019-09-20       Impact factor: 3.397

4.  A cross-sectional evaluation of the idiopathic pulmonary fibrosis patient satisfaction and quality of life with a care coordinator.

Authors:  Nathan Hambly; Sarah Goodwin; Afia Aziz-Ur-Rehman; Nima Makhdami; Margaret Ainslie-Garcia; Daniel Grima; Gerard Cox; Martin Kolb; Diana Fung; Czerysh Cabalteja; Patricia DeMarco; Daniel Moldaver
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

5.  Human antigen R promotes lung fibroblast differentiation to myofibroblasts and increases extracellular matrix production.

Authors:  Fatmah Al-Habeeb; Noof Aloufi; Hussein Traboulsi; Xingxing Liu; Parameswaran Nair; Christina Haston; Ilan Azuelos; Steven K Huang; Eric S White; Imed E Gallouzi; Sergio Di Marco; David H Eidelman; Carolyn J Baglole
Journal:  J Cell Physiol       Date:  2021-04-14       Impact factor: 6.513

6.  IL-24 deficiency protects mice against bleomycin-induced pulmonary fibrosis by repressing IL-4-induced M2 program in macrophages.

Authors:  Li-Zong Rao; Yi Wang; Lei Zhang; Guorao Wu; Lu Zhang; Fa-Xi Wang; Long-Min Chen; Fei Sun; Song Jia; Shu Zhang; Qilin Yu; Jiang-Hong Wei; Hui-Ren Lei; Ting Yuan; Jinxiu Li; Xingxu Huang; Bin Cheng; Jianping Zhao; Yongjian Xu; Bi-Wen Mo; Cong-Yi Wang; Huilan Zhang
Journal:  Cell Death Differ       Date:  2020-11-03       Impact factor: 15.828

7.  Comorbidities of Patients With Idiopathic Pulmonary Fibrosis in Four Latin American Countries. Are There Differences by Country and Altitude?

Authors:  Mauricio Gonzalez-Garcia; Emily Rincon-Alvarez; Maria Laura Alberti; Mauricio Duran; Fabian Caro; Maria Del Carmen Venero; Yuri Edison Liberato; Ivette Buendia-Roldan
Journal:  Front Med (Lausanne)       Date:  2021-06-17

8.  Mortality from idiopathic pulmonary fibrosis: a temporal trend analysis in Brazil, 1979-2014.

Authors:  Eduardo Algranti; Cézar Akiyoshi Saito; Diego Rodrigues Mendonça E Silva; Ana Paula Scalia Carneiro; Marco Antonio Bussacos
Journal:  J Bras Pneumol       Date:  2017 Nov-Dec       Impact factor: 2.624

9.  Estimating the incidence of interstitial lung diseases in the Cree of Eeyou Istchee, northern Québec.

Authors:  Matthieu Storme; Alexandre Semionov; Deborah Assayag; Michael Lefson; Darlene Kitty; David Dannenbaum; Jill Torrie; Pierre Lejeune; Elizabeth Robinson; Faiz Ahmad Khan
Journal:  PLoS One       Date:  2017-09-08       Impact factor: 3.240

Review 10.  Global incidence and prevalence of idiopathic pulmonary fibrosis.

Authors:  Toby M Maher; Elisabeth Bendstrup; Louis Dron; Jonathan Langley; Gerald Smith; Javaria Mona Khalid; Haridarshan Patel; Michael Kreuter
Journal:  Respir Res       Date:  2021-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.